CompletedNCT04566601

4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period for Borderline Personality Disorder

This study is completed in the United States, in Australia, in France, .... It is testing 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period for Borderline Personality Disorder.

Personality disorders, Borderline personalityDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether BI 1358894 may be useful for adults experiencing personality disorders.

What would participation involve?

Participants may receive BI 1358894, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Argentina, in Australia, and in Belgium.

Who is it mainly for?

This study appears to be mainly for adults with personality disorders.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record

Recruitment and eligibility
Is a site open, and who can take part?
Visits and time
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Study clarity

Things to check before joining

Study start dateStarted: November 13, 2020

Recruitment status: Completed
Enrollment listed in the registry: 390
Sponsor: Boehringer Ingelheim
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, Australia, France, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT04566601
Official title: A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period in Patients With Borderline Personality Disorder

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT04566601. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Anaheim, United States · Temecula, United States · Upland, United States

57 more locations

New Haven, United States
Fort Myers, United States
Gainesville, United States
Miami, United States
Alpharetta, United States
Belmont, United States
Flowood, United States
Cherry Hill, United States
Buffalo, United States
Cedarhurst, United States
Tulsa, United States
Wichita Falls, United States
Everett, United States
CABA, Argentina
Córdoba, Argentina
La Plata, Argentina
Rosario, Argentina
Frankston, Australia
Melbourne, Australia
Duffel, Belgium
Plovdiv, Bulgaria
Sofia, Bulgaria
Ostrava-Poruba, Czechia
Prague, Czechia
Aalborg, Denmark
Slagelse, Denmark
Bron, France
Montpellier, France
Aachen, Germany
Berlin, Germany
Bonn, Germany
Giessen, Germany
Mannheim, Germany
München, Germany
Tübingen, Germany
Brescia, Italy
Fukuoka, Fukuoka, Japan
Fukuoka, Kurume, Japan
Kanagawa, Kawasaki, Japan
Kanagawa, Yokohama, Japan
Nara, Kashihara, Japan
Tokyo, Chuo-ku, Japan
Tokyo, Shinjuku-ku, Japan
Mexico City, Mexico
Mérida, Mexico
Monterrey, Mexico
Querétaro, Mexico
San Luis Potosí City, Mexico
Bialystok, Poland
Gdansk, Poland
Santander, Spain
Seville, Spain
Valladolid, Spain
Enskede, Sweden
Gothenburg, Sweden
Uppsala, Sweden
Czechia

Registry details

Registry conditions (original wording)

Borderline Personality Disorder; borderline personality disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Does this study involve medication?

Yes. The study involves medication, including BI 1358894 and Placebo.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me

4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period for Borderline Personality Disorder

Key information made simple

What is this study testing?

What would participation involve?

Who is it mainly for?

What should you check before joining?

Check the study details

Recruitment and eligibility

Visits and time

Costs and support

Questions to ask before joining

Things to check before joining

Ask HopeStage to help me review this study

Recruitment & locations

Questions about this study

Want to find a study that may fit you better?

Explore related studies

"The Effects of Oxytocin on people with Borderline Personality Disorder"

A D1 Agonist For Working Memory

A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)